# Endocannabinoid System Clinical Research: Minder Mobile Mental Health RCT > **Author:** Benjamin Caplan, MD (ABFM Board Certified, MA Lic. #240562, NPI: 1962722637) > **Publisher:** CED Clinic (https://cedclinic.com) > **Canonical URL:** https://cedclinic.com/effectiveness-minder-mobile-mental-health-rct-findings/ > **Published:** 2026-03-15T14:14:49-04:00 | **Last Modified / Clinically Audited:** 2026-09-28T11:58:30-04:00 > **Clinical Summary:** Explore the effectiveness minder mobile mental health app in a randomized controlled trial addressing student mental health and substance use challenges. --- #### Clinical Takeaway A randomized controlled trial tested the Minder mobile app, co-developed with university students, to address mental health and [substance use](https://cedclinic.com/stroke-risk-assessment-substance-use/) challenges during the college transition period. Digital tools like this are being studied because they can reach large student populations with low barriers to access. Results from this trial provide evidence on whether app-based interventions can meaningfully improve outcomes in this high-risk demographic. ### #4 Effectiveness of the Minder Mobile Mental Health and Substance Use Intervention for University Students: Randomized Controlled Trial. **Citation:** Vereschagin Melissa et al. *Effectiveness of the Minder Mobile Mental Health and Substance Use Intervention for University Students: Randomized Controlled Trial.* Journal of medical Internet research. 2024. PMID: 38536225. **Study type:** Randomized Controlled Trial, Journal Article, Research Support, Non-U.S. Gov’t  |  **Topic area:** Anxiety & PTSD  |  **CED Score:** 12 Design: 5 Journal: 0 N: 3 Recency: 1 Pop: 2 Human: 1 Risk: 0 Why This Matters This study evaluates a scalable digital intervention addressing the critical gap in mental health and substance use support for university students, a population with high prevalence of emerging psychiatric and addictive disorders. The randomized controlled trial design provides rigorous evidence needed to determine whether mobile app-based interventions can effectively reduce symptoms and substance use in this high-risk developmental period. Given the demonstrated acceptability and feasibility of digital mental health tools, positive findings would support implementation of evidence-based mobile interventions as accessible first-line treatment options in university health systems. **Abstract:** BACKGROUND: University attendance represents a transition period for students that often coincides with the emergence of mental health and substance use challenges. Digital interventions have been identified as a promising means of supporting students due to their scalability, adaptability, and acceptability. Minder is a mental health and substance use mobile app that was codeveloped with university students. OBJECTIVE: This study aims to examine the effectiveness of the Minder mobile app in improving mental health and substance use outcomes in a general population of university students. METHODS: A 2-arm, parallel-assignment, single-blinded, 30-day randomized controlled trial was used to evaluate Minder using intention-to-treat analysis. In total, 1489 participants were recruited and randomly assigned to the intervention (n=743, 49.9%) or waitlist control (n=746, 50.1%) condition. The Minder app delivers evidence-based content through an automated chatbot and connects participants with services and university social groups. Participants are also assigned a trained peer coach to support them. The primary outcomes were measured through in-app self-assessments and included changes in general anxiety symptomology, depressive symptomology, and alcohol consumption risk measured using the 7-item General Anxiety Disorder scale, 9-item Patient Health Questionnaire, and US Alcohol Use Disorders Identification Test-Consumption Scale, respectively, from baseline to 30-day follow-up. Secondary outcomes included measures related to changes in the frequency of substance use (cannabis, alcohol, opioids, and nonmedical stimulants) and mental well-being. Generalized linear mixed-effects models were used to examine each outcome. RESULTS: In total, 79.3% (589/743) of participants in the intervention group and 83% (619/746) of participants in the control group completed the follow-up survey. The intervention group had significantly greater average reductions in anxiety symptoms measure Clinical Perspective This randomized controlled trial examining a student-codeveloped mental health and substance use app addresses a genuine gap in accessible digital interventions for a vulnerable transitional population. While the study’s strength lies in its focus on scalable, student-informed design and the university setting’s controlled research environment, clinicians should note that app-based interventions often show stronger efficacy in controlled trials than in real-world implementation, where adherence and sustained engagement typically decline significantly. The effectiveness of digital mental health tools also varies substantially based on underlying clinical presentation, baseline severity, and whether students engage with concurrent traditional care, factors that may not be fully captured in the trial design. Additionally, substance use outcomes in university populations can be influenced by multiple environmental and social factors beyond app features that are difficult to isolate in research. From a practical standpoint, while the Minder app may serve as a useful adjunctive screening and psychoeducational tool for your student patients presenting with emerging mental health or substance concerns, it should not replace comprehensive clinical assessment and individualized treatment  |   |  Further Reading CED Clinic Blog[Cannabis-Infused Beverages as Alcohol Alternatives: New York at Five Years](https://cedclinic.com/cannabis-beverage-substitution-alcohol-new-york-five-years/) Research Digest[AM Policy Update: March 11, 2026](https://cedclinic.com/dea-rescheduling-marijuana-march-11-2026/) Cannabis Policy Wire[Schedules of Controlled Substances: Temporary Placement of Bromazolam in Schedule I](https://cedclinic.com/temporary-scheduling-novel-benzodiazepines-bromazolam-update/) [View on PubMed ↗](https://pubmed.ncbi.nlm.nih.gov/38536225/)[Full Text ↗](https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11007604/)[DOI ↗](https://doi.org/10.2196/54287) [https://cedclinic.com/contact/](https://cedclinic.com/contact/) Physician-Led, Whole-Person Care A doctor who takes the time to truly understand you. Personal care that starts with listening and is guided by experience and ingenuity. Health, Longevity, Wellness One-on-One Cannabis Guidance Metabolic Balance [Leave a Message](https://cedclinic.com/contact/) [Metabolic Care](https://cedclinic.com/metabolic/metabolic-how-it-works/) [Medical Consulting](https://cedclinic.com/book/) [Cannabis Care](https://cedclinic.com/book/) [https://cedclinic.com/contact/](https://cedclinic.com/contact/) RELATED READING AT CED CLINIC Continue exploring the evidence [endocannabinoid system clinical research: mobile mental health](https://cedclinic.com/digital-mental-health-intervention-cannabis-rcts/) Explore [clinical research](https://cedclinic.com/cannabis-based-therapies-smoking-cessation/) on mobile mental health interventions targeting the [endocannabinoid system](https://cedclinic.com/endocannabinoid-system-fear-extinction/) and their impact on patient outcomes. [Read More](https://cedclinic.com/digital-mental-health-intervention-cannabis-rcts/) [endocannabinoid system clinical research: Cannabis RCT Evidence](https://cedclinic.com/digital-mental-health-intervention-cannabis-research-insights/) Review randomized controlled trials examining cannabis effects on the endocannabinoid system and clinical outcomes. [Explore Study](https://cedclinic.com/digital-mental-health-intervention-cannabis-research-insights/) [Endocannabinoid System Clinical Research: 2024 RCT Review](https://cedclinic.com/digital-mental-health-intervention-cannabis-research-2024/) A comprehensive review of 2024 randomized controlled trials focusing on the endocannabinoid system and clinical applications. [Learn More](https://cedclinic.com/digital-mental-health-intervention-cannabis-research-2024/) Have thoughts on this? Share it: [X Share on X](https://twitter.com/intent/tweet?text=Endocannabinoid%20System%20Clinical%20Research%3A%20Minder%20Mobile%20Mental%20Health%20RCT&url=https%3A%2F%2Fcedclinic.com%2Feffectiveness-minder-mobile-mental-health-rct-findings%2F) [in Share on LinkedIn](https://www.linkedin.com/sharing/share-offsite/?url=https%3A%2F%2Fcedclinic.com%2Feffectiveness-minder-mobile-mental-health-rct-findings%2F) [Share on BlueSky](https://bsky.app/intent/compose?text=Endocannabinoid%20System%20Clinical%20Research%3A%20Minder%20Mobile%20Mental%20Health%20RCT%20https%3A%2F%2Fcedclinic.com%2Feffectiveness-minder-mobile-mental-health-rct-findings%2F) [Follow on Instagram](https://www.instagram.com/drbenjamincaplan) [Read more on Substack](https://doctorapprovedcannabis.substack.com/) [Subscribe via RSS](https://cedclinic.com/feed/) ### Related --- ### Verification & Medical Governance - **Lead Clinical Author:** Benjamin Caplan, MD - **Credentials:** Board Certified in Family Medicine (ABFM), Former CMO Canna Care Docs (250,000+ patients supervised), Founder & CMO CED Clinic & CED Foundation, Author of *The Doctor-Approved Cannabis Handbook* (Penguin Random House). - **Clinical Scale:** 350,000+ lifetime evaluations overseen; 81,008-patient Real-World Evidence Registry (`~/.ced_rwe_vault.db`); 125,000+ peer-reviewed study literature observatory (`http://localhost:8768/api/explorer/terminal`). - **License Verification:** Commonwealth of Massachusetts License #240562 (https://checkahealthlicense.mass.gov/). - **NPI Registry:** 1962722637 (https://npiregistry.cms.hhs.gov/provider-view/1962722637). - **Ethics & Data Privacy:** Clinical registry observations adhere strictly to HIPAA Safe Harbor de-identification (45 CFR § 164.514(b)) and criteria for secondary research exemption under 45 CFR § 46.104(d)(4).